Biotech ETF XBI soars 25% this year as Big Pharma races to buy pipelines before patent cliffs hit

The biotech sector has mounted a sharp rebound driven by Big Pharma's urgent race to acquire new drug pipelines before patent cliffs erode their revenue base. The SPDR S&P Biotech ETF (XBI) has gained 25% this year and nearly 80% over the past 12 months, hitting its highest level since February 2021—a dramatic turnaround from the prolonged slump that followed the sector's pandemic-era boom.

The engine behind this rebound is patent expiration. Morningstar estimates that patent expirations could create a $139 billion（約22兆円） revenue headwind for the largest biopharma companies through 2030. Merck's top-selling cancer drug Keytruda and Bristol Myers Squibb's Opdivo—both major revenue drivers—face patent pressure around 2028 and 2029. Once exclusivity expires, cheaper generic or biosimilar competition will rapidly erode sales. This leaves large drugmakers with an uncomfortable choice: spend years and billions developing replacements internally, accepting significant clinical risk, or acquire companies whose drugs are already in late-stage trials or on the market.

Big Pharma has chosen acquisition. Pharma companies have acquired 37 biotech businesses valued at $1 billion（約1600億円） or more this year, already exceeding the previous annual record of 35, according to Stifel data cited by the Financial Times. Total biotech deal value has reached $216 billion（約35兆円）, nearly doubling from $118 billion（約19兆円） last year. The deals are strikingly large and focused on near-ready assets. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion（約1.6兆円）, its largest-ever takeover. AbbVie struck a $10.9 billion（約1.7兆円） deal for Apogee Therapeutics' late-stage immunology pipeline. GSK paid $10.6 billion（約1.7兆円） for Nuvalent to strengthen its oncology portfolio with two FDA-review lung cancer drugs. Eli Lilly, fueled by obesity-drug windfalls, has emerged as the industry's most aggressive buyer, most recently agreeing to acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion（約6100億円） while funding acquisitions across oncology, neuroscience, and genetic medicines.

With several high-profile targets already acquired, investors are hunting for the next wave of deals. Viking Therapeutics remains a leading candidate, with injectable and oral versions of obesity drug VK2735 offering buyers exposure to a GLP-1 market that Morningstar expects could approach $200 billion（約32兆円） by 2035. Other potential targets include Structure Therapeutics, Revolution Medicines, Legend Biotech, Incyte, BioMarin, Ionis Pharmaceuticals, and Moderna. Syndax Pharmaceuticals and BioCryst Pharmaceuticals may appeal to buyers seeking more de-risked commercial assets. At the more speculative end, Sellas Life Sciences has recorded 78 of the 80 events needed to trigger the final analysis of its Phase 3 Regal trial of galinpepimut-S in AML, putting it close to a pivotal readout; a positive survival outcome could boost its case as a late-stage oncology target.

Yet a striking disconnect exists between the sector's technical strength and retail sentiment. On Stocktwits, retail sentiment toward XBI fell to a record-low score of 21 out of 100, shifting to 'extremely bearish' from 'bearish' a day earlier, amid 'low' message volume. The ticker's watcher count has risen only a modest 4% over the past year. One user commented that it was 'time for the $XBI to cool off and build out a handle,' while another highlighted the heavy concentration of put open interest around the $150 strike heading into the July 31 expiration as a key level to watch. This extreme bearishness amid strong price momentum suggests either a capitulation opportunity or a warning sign of unsustainable momentum.

The biotech sector's resurgence reflects a structural problem facing the pharmaceutical industry: a looming patent cliff that threatens to erase hundreds of billions in annual revenue. As major blockbuster drugs lose exclusivity around 2028–2029, generic and biosimilar competitors will rapidly erode sales, forcing large drugmakers to choose between costly, multi-year internal development programs or faster acquisitions of proven late-stage assets. This creates a powerful and time-bound incentive to buy, evident in the unprecedented deal velocity: 37 billion-dollar-plus biotech acquisitions already this year, versus 35 for all of last year, and a near-doubling of total deal value to $216 billion（約35兆円）.

Elי Lilly has emerged as the most aggressive buyer, using cash generated by its blockbuster obesity drug to fund acquisitions across oncology, neuroscience, and genetic medicines. Other pharma giants—Vertex, AbbVie, and GSK—are striking comparable deals, each in the $10 billion（約1.6兆円） range, for companies with drugs that either have FDA approvals in sight or are already commercialized. This M&A wave is expected to continue, with analysts watching companies like Viking Therapeutics (which offers access to the emerging GLP-1 obesity drug market) as prime takeover candidates.

Paradoxically, despite the XBI biotech ETF's strong technical performance—up 25% this year and nearly 80% over 12 months, hitting a seven-year high—retail sentiment toward the sector has collapsed to a record low of 21 out of 100 on Stocktwits, an unusual disconnect that suggests either a late-stage momentum trade or a genuine mispricing of risk as the broader market reprices biotech amid structural buyout pressure.

No comments yet. Be the first to share your thoughts!